GM-CSF as a therapeutic target in psoriasis: randomised, controlled investigation using namilumab - a specific, human anti-GM-CSF monoclonal antibody.
CONCLUSIONS: GM-CSF blockade is not critical for suppression of key inflammatory pathways underlying psoriasis (NCT02129777). This article is protected by copyright. All rights reserved.
PMID: 30207587 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Papp KA, Gooderham M, Jenkins R, Vender R, Szepietowski JC, Wagner T, Hunt B, Souberbielle B, NEPTUNE investigators Tags: Br J Dermatol Source Type: research